» GTx exploring product candidate as potential Duchenne treatment Action Duchenne: "GTx is exploring SARM, their lead product candidate, a selective androgen receptor modulator as potential treatment for Duchenne muscular dystrophy.
Preclinical studies have confirmed the beneficial effects from SARMs in mice genetically altered to simulate Duchenne muscular dystrophy, compared to control groups. The Company continues to pursue a potential strategic collaboration with biopharma companies experienced in orphan drug development."
'via Blog this'
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment